Nicotinamide riboside (NR) failed as a treatment for early Parkinson’s disease.
It actually made symptoms modestly worse, by the end of one year.
This is a supplement commonly taken for “anti-aging” to raise levels of NAD+. This study highlights that it may have downsides in certain conditions.
Quoted from the original post:
In a phase 3 trial of oral Nicotinamide Riboside for early Parkinson’s Disease treatment, the intervention did not improve clinical outcomes compared with placebo at 52 weeks. Patients receiving nicotinamide riboside had modestly worse scores on the MDS-UPDRS (Movement Disorder Society Unified Parkinson Disease Rating Scale), a measure of motor and non-motor symptoms. The findings are clinically relevant given widespread use of this supplement and ongoing related trials.
📌 Learn more:
Paper · JAMA · 2026Nicotinamide Riboside for Patients With Early-Stage Parkinson DiseaseImportance Nicotinamide riboside, a nicotinamide adenine dinucleotide precursor, has been proposed as a potential disease-modifying therapy for Parkinson disease based on preclinical and early studies. Whether prolonged oral nicotinamide riboside improves clinical outcomes in Parkinson disease is unknown. Objective To determine whether nicotinamide riboside improves clinical outcomes in Parkinson disease compared…jamanetwork.com
